The MAGiC catheter is a robotically navigated magnetic ablation catheter that performs minimally invasive cardiac ablation procedures. The first procedures were performed in Lithuania in eight patients following receipt of approvals to begin enrollment in the prospective clinical trial.
“We were delighted to perform the first procedures using the MAGiC catheter, and were pleased with the performance,” said Assoc. Prof. Gediminas Račkauskas at Vilnius University Hospital Santaros Klinikos. “The catheter was very stable, effective and safe. We look forward to continued enrollment in the coming weeks. The electrophysiology community has long awaited innovation in robotic catheter technology, and we are excited to support this progress.”
Data from the clinical trial will support Stereotaxis’ CE Mark submission of MAGiC.
“This is a significant milestone for Stereotaxis as we advance our comprehensive innovation strategy,” CEO David Fischel said in a news release. “We look forward to the impact MAGiC, a key pillar in our new product ecosystem, will have on patients, physicians, and the advancement of medicine.”
Stereotaxis is the creator of surgical robotics innovations for minimally invasive endovascular intervention. Its technology has been used to treat over 100,000 patients in the U.S., Europe, Asia and elsewhere in the world.
